Frazier Life Sciences Management, L.P.
Position in PVLA — Palvella Therapeutics, Inc.
CIK 1892134
PALO ALTO, CA
Position in PVLA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$109,991,160
+$34,377,552 QoQ
Shares Held
882,400
+22.1% QoQ
Ownership
6.15%
of shares outstanding
% of Portfolio
2.84%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in PVLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Frazier Life Sciences Management, L.P. holds $3,802,745,091 across 34 Biotechnology names. PVLA ranks #11 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MIRM |
Mirum Pharmaceuticals, Inc.
|
7,679,684 | $709,449,207 | |
| 2 | NAMS |
NewAmsterdam Pharma Co N.V.
|
16,943,774 | $542,370,205 | |
| 3 | ERAS |
Erasca, Inc.
|
24,675,188 | $399,244,541 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
3,448,139 | $256,058,802 | |
| 5 | ARQT |
Arcutis Biotherapeutics, Inc.
|
9,874,511 | $232,643,479 | |
| 6 | MBX |
MBX Biosciences, Inc.
|
6,652,013 | $198,562,588 | |
| 7 | PHAT |
Phathom Pharmaceuticals, Inc.
|
12,466,489 | $138,502,692 | |
| 8 | MAZE |
Maze Therapeutics, Inc.
|
4,567,274 | $136,333,128 |
All Filings in PVLA
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $109,991,160 | 882,400 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $75,613,608 | 722,400 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $45,287,256 | 722,400 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $16,282,896 | 722,400 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $19,313,435 | 690,012 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $7,846,704 | 653,892 | Shares | Sole | 2025-02-18 | |
| No filing history on record for this holder in this stock. | ||||||